Pancreatitis (Pancreas inflammation): Types, Symptoms, Medicines, Prevention

PancreatitisThe modern way of life has many benefits, but, unfortunately, it does not always contribute to a high state of health. Fast food and snacks on the go, stress, and lack of healthy sleep – all these factors can lead to disorders of the digestive system. Pancreatitis is one of the most common diseases. The pancreas becomes inflamed, and if the condition worsens, the tissues of the organ can be destroyed. This leads to the inability of the organ to function normally. In addition, if the problem is not treated in time, complications may arise, namely bacterial infection. It is important to recognize the symptoms of pancreatitis and consult a doctor at the onset of symptoms.

The increase in morbidity

Recently, an increase in pancreatitis has been recorded in the adult population around the world. Statistics say that over the past thirty years alone, the number of people suffering from the disease has increased by two times, including in Canada. But it should be noted that this is only according to official statistics. Many people refuse to seek help from a doctor, even with regular pain. This chronic disease affects from 0.2% to 0.68% of people worldwide.

In addition, the problem is particularly acute in developed countries, as the age of onset for the disease has greatly decreased. A couple of decades ago, it was mostly elderly people who suffered from pancreatitis. Today, many patients are not yet forty years old. The proportion of women with pancreatitis has also increased. Separately, the indicator for patients whose condition is directly related to alcohol dependence has grown from 40% to 80%.

If the problem is ignored, then chronic pancreatitis can turn into pancreatic cancer.

Types of disease

Doctors distinguish two forms of pancreatitis depending on the condition and complexity. The acute form manifests itself quickly and imperceptibly. The acute form is especially dangerous for the patient, so it is often necessary to resort to surgical methods. The chronic form can last for years and will not disappear without competent treatment. Generally, for chronic pancreatitis, the patient can be treated independently at home by observing the doctor’s recommendations and taking the prescribed medications. In addition, a patient with chronic pancreatitis should be regularly tested and monitored by a doctor.

Pancreatitis can be further divided into categories depending on the cause:

  • Medicinal
  • Autoimmune
  • Infectious
  • Dysmetabolic
  • Biliary dependent
  • Alcoholic

It should be noted that the cause of the disease does not play an important role in choosing a medicine, but doctors can give recommendations and indicate preventive measures to avoid the development of the disease in the future.

Symptoms of Pancreatitis

The cause of pancreatitis has a major influence on the exhibited symptoms. The chronic type can occur without any symptoms at all, which is even more dangerous for the patient. In the acute form, the patient feels severe pain in the left upper abdomen. Other symptoms include:

  • nausea and vomiting
  • increase in body temperature
  • bloating
  • diarrhea or stool retention
  • yellowing of the skin and sclera
  • rapid heartbeat
  • unexplained weight loss

Without proper treatment, the symptoms of the disease will not go away. In addition, symptoms may be intermittent. It is necessary to treat the cause of pancreatitis and not just the symptoms.

Causes

Pancreatitis is formed by the premature activation of digestive enzymes. Normally, these substances are transported to the intestine in an inactive form, but in pathological conditions, enzymes begin destroying the pancreas. Pathogens can migrate to the organ from other parts of the digestive system through the blood and lymph.

Factors causing inflammation of the pancreas are:

  • abuse of alcoholic beverages
  • cholelithiasis
  • uncontrolled medication intake
  • viral and bacterial infections
  • smoking
  • high concentration of triglycerides and calcium in the blood
  • violation of the functions of the immune system
  • anatomical defects in which there is a delay of enzymes in the organ
  • inflammation of the intestine and bile ducts
  • abdominal injury
  • malignant tumor of the pancreas

The causes of acute and chronic pancreatitis may differ, but the highest risk factors are alcoholism and diseases of the biliary tract.

Which medicine is right for me?

Your doctor will prescribe the best treatment for you after a thorough evaluation of your medical history and symptoms. The choice of drug and dosage depends on the patient’s condition and the complexity of the disease. The easiest way to get medication for pancreatitis is to order them from an online rx service, such as Canadian pharmacy, which many people use for its accessibility and variety of options. The chronic disease requires regular medical examination and analysis. Each drug has specific instructions for the dosage and method of use. Follow the advice of your doctor when taking medication. These are the primary drugs prescribed for the treatment of pancreatitis:

  • Omnipen (ampicillin)
  • Primaxin Iv (imipenem/cilastatin)
  • Rocephin (ceftriaxone sodium)
  • Creon (Pancrelipase)
  • Gemcitabine

Each drug has its own contraindications and side effects, so it is important to consult a doctor before taking any medication.

Prevention of Pancreatitis

Compliance with preventive measures can save you from many problems in the future. Doctors advise the following guidelines not only for patients with chronic pancreatitis but also for everyone who wants to be healthy.

  • Eat low-fat foods.
  • Try not to snack, especially fast food
  • Do not drink alcohol.
  • Drink as much water as possible per day.
  • Be physically active.

These guidelines will help reduce the risk of developing pancreatitis. In the case of chronic pancreatitis, compliance with the guideline is mandatory for optimal results.

Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors

SAN DIEGO, Feb. 19, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has enrolled and begun dosing the final patient in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed, MGMT-unmethylated glioblastoma multiforme (GBM).

Continue reading Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors

Canada Pharmacy Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083

SAN DIEGO, March 4, 2020 /PRNewswire/ — Canada Pharmacy, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced it has exceeded 50% enrollment in the adjuvant arm of the Company’s ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide — or TMZ – maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) with VAL-083. The 24-patient, open label study arm has now enrolled 14 patients and continues to enroll at an encouraging rate.

Continue reading Canada Pharmacy Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083

Canadian Pharmacy Receives Nasdaq Bid Price Extension

SAN DIEGO, March 26, 2020 /PRNewswire/ — Canadian Pharmacy, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that it has received a listing extension from the Staff of the Listing Qualifications Department of The Nasdaq Capital Market LLC (Nasdaq). The extension grants the Company until September 21, 2020 to regain compliance with the $1.00 Minimum Bid Price requirement for continued listing on Nasdaq.

Continue reading Canadian Pharmacy Receives Nasdaq Bid Price Extension

Positive Interim Data on VAL-083

Findings Support Commencement of VAL-083’s Participation in Pivotal GCAR GBM AGILE Study

SAN DIEGO, June 22, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM) demonstrating improved outcomes over current standard of care as both a first-line treatment and for recurrent GBM.

Continue reading Positive Interim Data on VAL-083

DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates

Download as PDF 

Related Documents

PDF HTML 10-Q Filing ZIP XLS HTML XBRL

SAN DIEGO, Feb. 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the three and six months ended December 31, 2019 and provided a corporate update.

Continue reading DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates

Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 13, 2019 /PRNewswire/ — Trust pharmacy, a biopharmaceutical company focused on the development of novel cancer therapies, provided an update on the first 20 patients enrolled in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 in combination with radiation therapy in newly-diagnosed, MGMT-unmethylated GBM.

Continue reading Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083

DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering

Download as PDF

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced the pricing of an underwritten public offering of 6,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to an aggregate of 6,750,000 shares of common stock.

Continue reading DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering

DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

Download as PDF

Related Documents

PDF HTML 10-K Filing ZIP XLS HTML XBRL

Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020

SAN DIEGO, Sept. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2019.

Continue reading DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

DelMar Pharmaceuticals Receives Nasdaq Listing Extension

Download as PDF

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 7, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced that it has received a listing extension from the Nasdaq Hearings Panel. The extension grants the Company until June 25, 2019 to regain compliance with the Minimum Bid Price requirement for continued listing on The Nasdaq Capital Market LLC (Nasdaq).

Continue reading DelMar Pharmaceuticals Receives Nasdaq Listing Extension